These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

621 related items for PubMed ID: 24367037

  • 1. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E, Louapre C, Lubetzki C, Papeix C.
    Mult Scler; 2014 Apr; 20(4):505-9. PubMed ID: 24367037
    [Abstract] [Full Text] [Related]

  • 2. Comment on 'Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?' Maillart et al.
    Tur C, Montalban X.
    Mult Scler; 2014 Apr; 20(4):510-1. PubMed ID: 24468818
    [No Abstract] [Full Text] [Related]

  • 3. Severe relapses under fingolimod treatment prescribed after natalizumab.
    Centonze D, Rossi S, Rinaldi F, Gallo P.
    Neurology; 2012 Nov 06; 79(19):2004-5. PubMed ID: 23035063
    [No Abstract] [Full Text] [Related]

  • 4. Switching from natalizumab to fingolimod: an observational study.
    Sempere AP, Martín-Medina P, Berenguer-Ruiz L, Pérez-Carmona N, Sanchez-Perez R, Polache-Vengud J, Feliu-Rey E.
    Acta Neurol Scand; 2013 Aug 06; 128(2):e6-e10. PubMed ID: 23336398
    [Abstract] [Full Text] [Related]

  • 5. Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?
    Wipfler P, Harrer A, Pilz G, Oppermann K, Afazel S, Haschke-Becher E, Sellner J, Trinka E, Kraus J.
    Acta Neurol Scand; 2014 Mar 06; 129(3):e12-5. PubMed ID: 24032536
    [Abstract] [Full Text] [Related]

  • 6. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
    Gajofatto A, Bianchi MR, Deotto L, Benedetti MD.
    Eur Neurol; 2014 Mar 06; 72(3-4):173-80. PubMed ID: 25226868
    [Abstract] [Full Text] [Related]

  • 7. Fingolimod and multiple sclerosis: four cautionary tales.
    Bourdette D, Gilden D.
    Neurology; 2012 Nov 06; 79(19):1942-3. PubMed ID: 23035058
    [No Abstract] [Full Text] [Related]

  • 8. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
    Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K.
    Am J Manag Care; 2013 Apr 06; 19(4):278-85. PubMed ID: 23725360
    [Abstract] [Full Text] [Related]

  • 9. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.
    Duodecim; 2013 Apr 06; 129(7):765-70. PubMed ID: 23720945
    [Abstract] [Full Text] [Related]

  • 10. [[Natalizumab therapy, 2013].
    Karácsony M, Bencsik K, Vécsei L.
    Ideggyogy Sz; 2014 Jul 30; 67(7-8):220-8. PubMed ID: 25509362
    [Abstract] [Full Text] [Related]

  • 11. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 12. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS.
    J Neurol Sci; 2011 Dec 17; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [Abstract] [Full Text] [Related]

  • 13. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE.
    Curr Opin Neurol; 2006 Aug 17; 19(4):341-9. PubMed ID: 16914971
    [Abstract] [Full Text] [Related]

  • 14. Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden.
    Bergvall N, Tambour M, Henriksson F, Fredrikson S.
    J Med Econ; 2013 Aug 17; 16(3):349-57. PubMed ID: 23211038
    [Abstract] [Full Text] [Related]

  • 15. Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis.
    Crespo C, Izquierdo G, García-Ruiz A, Granell M, Brosa M.
    Neurologia; 2014 May 17; 29(4):210-7. PubMed ID: 24161412
    [Abstract] [Full Text] [Related]

  • 16. Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation.
    Berger B, Baumgartner A, Rauer S, Mader I, Luetzen N, Farenkopf U, Stich O.
    J Neuroimmunol; 2015 May 15; 282():118-22. PubMed ID: 25903738
    [Abstract] [Full Text] [Related]

  • 17. [Dilemma of further therapeutic step in remitting-relapsing multiple sclerosis in case of ineffectiveness of first-line treatment: fingolimod or natalizumab?].
    Gábor L.
    Ideggyogy Sz; 2014 Mar 30; 67(3-4):141. PubMed ID: 26118259
    [No Abstract] [Full Text] [Related]

  • 18. Early onset of natalizumab-related progressive multifocal leukoencephalopathy.
    Damasceno A, von Glehn F, Martinez AR, Longhini AL, Deus-Silva L, Brandão CO, Santos LM, Damasceno BP.
    Mult Scler; 2011 Nov 30; 17(11):1397-8. PubMed ID: 21900356
    [No Abstract] [Full Text] [Related]

  • 19. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
    Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugaresi A, Izquierdo G, Rozsa C, Grammond P, Alroughani R, Duquette P, Girard M, Pucci E, Lechner-Scott J, Slee M, Fernandez-Bolanos R, Grand'Maison F, Hupperts R, Verheul F, Hodgkinson S, Oreja-Guevara C, Spitaleri D, Barnett M, Terzi M, Bergamaschi R, McCombe P, Sanchez-Menoyo J, Simo M, Csepany T, Rum G, Boz C, Havrdova E, Butzkueven H, MSBase Study Group.
    Ann Neurol; 2015 Mar 30; 77(3):425-35. PubMed ID: 25546031
    [Abstract] [Full Text] [Related]

  • 20. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
    Baldi E, Guareschi A, Vitetta F, Senesi C, Curti E, Montepietra S, Simone AM, Immovilli P, Caniatti L, Tola MR, Pesci I, Montanari E, Sola P, Granella F, Motti L, Ferraro D.
    Curr Med Res Opin; 2014 Sep 30; 30(9):1849-55. PubMed ID: 24831186
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.